ICON Public Limited Company (ICLR) Revenue History
Annual and quarterly revenue from 2013 to 2024
Compound Annual Growth Rate (CAGR)
Loading revenue history...
ICLR Revenue Growth
Revenue Breakdown (FY 2012)
ICLR's revenue distribution by segment and geography for fiscal year 2012
By Product/Segment
By Geography
ICLR Revenue Analysis (2013–2024)
As of May 8, 2026, ICON Public Limited Company (ICLR) generated trailing twelve-month (TTM) revenue of $8.10 billion, reflecting modest growth of +0.6% year-over-year. The most recent quarter (Q3 2025) recorded $2.04 billion in revenue, up 1.3% sequentially.
Looking at the longer-term picture, ICLR's 5-year compound annual growth rate (CAGR) stands at +24.2%, indicating outstanding long-term growth trajectory. The company achieved its highest annual revenue of $8.28 billion in 2024, representing a new all-time high.
Revenue diversification analysis shows ICLR's business is primarily driven by Clinical Research (92%), and Central Laboratory (8%). With over half of revenue concentrated in Clinical Research, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including CRL (+0.1% YoY), IQV (+7.3% YoY), and MEDP (+24.2% YoY), ICLR has underperformed the peer group in terms of revenue growth. Compare ICLR vs CRL →
ICLR Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| ICLRCurrent | $8.1B | +0.6% | +24.2% | 13.3% | |
 CRL | $4.0B | +0.1% | +6.5% | 12.6% | |
 IQV | $16.3B | +7.3% | +7.5% | 14.0% | |
 MEDP | $2.5B | +24.2% | +22.3% | 21.1% | |
 PRA | $1.1B | -3.2% | +4.4% | 6.6% | |
 LH | $14.0B | +7.3% | -0.0% | 10.9% |
ICLR Historical Revenue Data (2013–2024)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | $8.28B | +2.0% | $2.44B | 29.4% | $1.10B | 13.3% |
| 2023 | $8.12B | +4.9% | $2.40B | 29.6% | $956.2M | 11.8% |
| 2022 | $7.74B | +41.2% | $2.21B | 28.6% | $795.2M | 10.3% |
| 2021 | $5.48B | +95.9% | $1.51B | 27.5% | $378.5M | 6.9% |
| 2020 | $2.80B | -0.3% | $808.0M | 28.9% | $391.5M | 14.0% |
| 2019 | $2.81B | +8.1% | $831.7M | 29.6% | $433.4M | 15.4% |
| 2018 | $2.60B | +47.6% | $769.5M | 29.6% | $373.4M | 14.4% |
| 2017 | $1.76B | +5.5% | $727.0M | 41.3% | $338.3M | 19.2% |
| 2016 | $1.67B | +5.8% | $705.2M | 42.3% | $311.7M | 18.7% |
| 2015 | $1.57B | +4.8% | $666.0M | 42.3% | $281.5M | 17.9% |
Full ICLR Stock Analysis
Analyst consensus, bull case, AI-generated risk factors, and peer comparison — all in one place.
See ICLR's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs ICLR Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare ICLR vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonICLR — Frequently Asked Questions
Quick answers to the most common questions about buying ICLR stock.
Is ICLR's revenue growth accelerating or slowing?
ICLR revenue growth slowed to +0.6%, below the 5-year CAGR of +24.2%. TTM revenue is $8.1B. The deceleration marks a shift from historical growth rates.
What is ICLR's long-term revenue growth rate?
ICON Public Limited Company's 5-year revenue CAGR of +24.2% reflects the variable expansion pattern. Current YoY growth of +0.6% is near this long-term average.
How is ICLR's revenue distributed by segment?
ICLR reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2013-2024 are available for download. Segment mix reveals concentration and diversification trends.